Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Status:
Completed
Trial end date:
2019-04-25
Target enrollment:
Participant gender:
Summary
This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436)
and trametinib (GSK1120212) combination therapy with vemurafenib.